For research purposes only — These compounds aren't FDA approved. All data presented is from clinical trials for educational reference.
Cagrilintide
Metabolic Research Peptide
Dosage
Quantity
Price
$59.99
Free shipping on orders $150+
60-day money-back guarantee
Secure checkout
Made in the USA
Certificate of Analysis
Batch verified lab data
99.93%
Purity
- Variant
- Cagrilintide 10mg
- Lot #
- A0112
- Labeled
- 20mg
- Actual
- 22.56mg
- Tested
- Feb 4, 2026
Frequently Researched Together
View allResearch Purposes Snapshot
Cagrilintide is a long-acting amylin receptor agonist (with calcitonin-receptor activity) advanced by Novo Nordisk for obesity and type 2 diabetes, often discussed with semaglutide as CagriSema. Summaries below cite public Phase 2/3 disclosures (e.g., REDEFINE, REIMAGINE). This research-grade listing is not a drug approval, prescribing information, or treatment recommendation.
10.8%
Weight loss
Phase 2 monotherapy (~26 weeks) at 4.5 mg weekly in dose-ranging work (Lancet-family publications).
20.4%
With semaglutide
CagriSema arm in REDEFINE 1 (~68 weeks) vs comparators—combo greater than either alone.
~7 d
Half-life
Extended PK enabling once-weekly subcutaneous dosing in development narratives.
2
Receptor targets
Amylin-family agonism with calcitonin receptor engagement (dual incretin-adjacent biology).
3,400+
Trial participants
REDEFINE 1 scale (~3,417 adults) across multinational obesity/T2D-risk cohorts.
Development status
Where the program stands
- Developer
- Novo Nordisk
- Primary focus
- Obesity & metabolic disease
- Flagship trials
- REDEFINE 1–2; REIMAGINE 1–2
- Regulatory note
- CagriSema NDA timeline—verify FDA / company press releases for current status
Why amylin matters
A different appetite axis
GLP-1 agonists dominate incretin-driven satiety; amylin analogs engage parallel homeostatic and hedonic feeding circuits. CagriSema stacks GLP-1 (semaglutide) with cagrilintide to test whether pathways are additive.
- Semaglutide (Wegovy)GLP-1
- Tirzepatide (Zepbound)GLP-1 + GIP
- CagrilintideAmylin + CTR
- CagriSemaAmylin + GLP-1
What researchers observed
Phase 2 monotherapy and Phase 3 combination readouts (public summaries)
REDEFINE 1 — Phase 3 (~68 weeks)
−20.4%
Mean weight change — CagriSema arm
Weight change by arm (illustrative bars)
~3,417 adults with obesity or overweight plus comorbidities; multinational program; detailed results appear in NEJM (2025) and sponsor materials—confirm estimands in the primary paper.
REDEFINE 1 milestones
Responder analyses (CagriSema)
≥5% loss is a common clinically meaningful threshold; most combination participants exceeded it in reported analyses.
Cross-trial context
Not head-to-head
- CagriSema20.4%
- Semaglutide 2.4 mg14.9%
- Tirzepatide 15 mg (other trial)~22.5%
- Retatrutide 12 mg (other trial)~28.7%
Different eligibility, background meds, and visit schedules make naive ranking unreliable—only randomized comparisons within a trial are definitive.
Cagrilintide monotherapy — Phase 2 (~26 weeks)
Dose-ranging obesity study (Lancet-track publication)
- 4.5 mg−10.8%
- 2.25 mg−9%
- 1.2 mg−7.4%
- 0.6 mg−6%
- Liraglutide 3 mg (comparator)−9%
Beyond weight loss
Cardiometabolic and PRO signals from sponsor-reported analyses
−13.4 cm
Waist
REDEFINE 1 vs placebo on central adiposity.
−6.7
Systolic BP (mmHg)
Clinically meaningful BP shift vs placebo in summaries.
−1.91%
HbA1c
REIMAGINE 2 — CagriSema vs semaglutide monotherapy in T2D.
PROs ↑
Quality of life
IWQOL-Lite-CT & SF-36 physical domains improved in reported analyses.
Appetite regulation
Dual pathway modulation
Cagrilintide is framed as engaging hypothalamic homeostatic hunger and hindbrain/septal hedonic reward nodes—areas incompletely covered by GLP-1 monotherapy in mechanistic reviews.
Clinical significance: complementary amylin signaling may explain incremental loss when layered on semaglutide (~5.5% delta in REDEFINE 1).
Type 2 diabetes
REIMAGINE 2 snapshot
- HbA1c — CagriSema−1.91%
- HbA1c — Semaglutide−1.76%
- Weight — CagriSema−14.2%
- Weight — Semaglutide−10.2%
Sponsor-reported figures note absence of a clear weight plateau for CagriSema at week 68 in that dataset.
Cardiometabolic
REDEFINE 1 markers
Waist and systolic BP improvements accompany weight loss; interpret as trial-context associations, not guaranteed real-world effects.
- Waist −13.4 cm vs placebo narrative
- SBP −6.7 mmHg vs placebo narrative
Side effects observed in trials
GI-heavy profile typical of incretin / amylin-class agents
Most events were mild to moderate and attenuated with continued therapy; rates below reflect combination-heavy arms in public REDEFINE disclosures—always read the primary safety table.
Frequently reported AEs (approximate)
Nausea
MildConstipation
MildDiarrhea
MildVomiting
ModerateInjection site
MildDiscontinuation
AE-related stops (REDEFINE 1 context)
- CagriSema5.9%
- Semaglutide3.6%
- Cagrilintide2.6%
- Placebo2.6%
- Most stops clustered during dose escalation.
- GI intolerance was the leading driver.
- Combination GI burden exceeds either monotherapy in many tables.
- Long-term (>68 week) safety still accruing in open-label extensions.
- Pancreatic monitoring remains standard for amylin-class agents.
- Polypharmacy with other metabolic peptides requires formal interaction review.
- Investigational status persists where no marketing authorization exists.
Storage handling reference
Peptide handling
Cold
Cold chain per COA; do not assume room-temp OK.
Reconstitution
Sterile SC technique if applicable.
Light
Limit light exposure during prep.
Traceability
Document lot, strength, and diluent.
Researcher notes
- Top-line GI percentages often come from CagriSema arms—monotherapy AE rates can be lower.
- Nausea/vomiting are dose-escalation phenomena that typically improve with time on stable doses.
- Always reconcile web infographics with NEJM / sponsor supplements for exact denominators.
- Regulatory filings move quickly; verify FDA acceptance letters before citing precise submission dates.
Important Research Notice
Not for human consumption. This product and all products are sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from journals and official publications but should be fact checked. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations and you do not intend to use it for human consumption.